Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism

Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism

Abstract. Current guidelines recommend low-molecular-weight-heparins (LMWH) monotherapy for 3 to 6 months as first-line treatment for cancer-associated venous thromboembolism (VTE). In clinical practice, enoxaparin and nadroparin are common agents used. However, differences in therapy adherence betw...

Full description

Bibliographic Details
Main Authors: Sake J. van der Wall, Frederikus A. Klok, Paul L. den Exter, Deisy Barrios, Raquel Morillo, Suzanne C. Cannegieter, David Jimenez, Menno V. Huisman
Format: Article
Language:English
Published: Wolters Kluwer 2018-02-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000019

Internet

http://journals.lww.com/10.1097/HS9.0000000000000019

Similar Items